ALKEMNSEALKEM LABORATORIES LTD.HighNeutral
Announced Mon, 17 Aug · 19:00 IST

Alkem Labs shareholders approve Adroit Biomed amalgamation with 99.99% votes

Nclt Scheme FiledStrategic Transactions View source PDFExplain this filing

ALKEM · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+0.2%1-day move
₹5374.00
prior close
₹5374.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+1.2+1.0+1.6+1.7+0.2+0.5+0.5-0.4-0.5-0.5-3.6-0.3
Up moveDown movePending
AI summary

Alkem Laboratories held its NCLT-convened equity shareholders meeting on August 17, 2026 to approve the scheme of amalgamation with Adroit Biomed Limited. Shareholders voted overwhelmingly in favor at 99.9999%, with over 99.98 million valid votes polled on total outstanding shares. The special resolution was passed with the requisite majority under Sections 230-232 of the Companies Act, 2013. The scheme now moves toward NCLT sanction and other regulatory approvals before becoming effective.

Likely market impact

Shareholders have approved Adroit Biomed's merger into Alkem. The deal now moves toward NCLT sanction and other regulatory clearances before taking effect.